Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Buntanetap in Alzheimer's Disease
NCT07757204Phase 3Not yet recruiting
- Sponsor
- Annovis Bio, Inc.
- Start
- Sep 2026
- Primary completion
- Feb 2030
01
Overview
A Phase 3 trial of buntanetap in Alzheimer's disease (AD), sponsored by Annovis Bio, Inc.. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
buntanetap
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07757204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07757204.